Claims
- 1. A fusion polypeptide comprising a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID NO: 10, wherein x is 110 to 173 and y is 179 to 270, fused to a second heterologous polypeptide, and wherein the fusion polypeptide is capable of forming a trimer.
- 2. A fusion polypeptide comprising a first polypeptide consisting of amino acids x to y of the polypeptide depicted in SEQ ID NO: 10, wherein x is 110 to 173 and y is 179 to 270 with at least one substitution of an amino acid, wherein the first polypeptide is at least 80% identical to the polypeptide depicted in SEQ ID NO: 10 and the ability to trimerize is retained, and wherein said first polypeptide is fused to a second heterologous polypeptide.
- 3. The fusion polypeptide of claim 1, wherein the first polypeptide consists of amino acids 154 to 203 of the polypeptide depicted in SEQ ID NO: 10.
- 4. The fusion polypeptide of claim 1, 2 or 3, wherein the second polypeptide is a soluble portion of a tumor necrosis factor receptor super family (TNFRSF).
- 5. The fusion polypeptide of claim 4, wherein the second polypeptide is a soluble portion of a tumor necrosis factor super family (TNFSF) ligand.
- 6. The fusion polypeptide of claim 5, wherein the second polypeptide is a soluble portion of a polypeptide selected from the group consisting of TNFRSF1A, TNFRSF1B, TNFRSF3, TNFRSF4, TNFRSF5, TNFRSF6, TNFRSF6B, TNFRSF7, TNFRSF8, TNFRSF9, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF11B, TNFRSF12, TNFRSF12L, TNFRSF13, TNFSF13B, TNFRSF14, TNFRSF15, NFRSF16, TNFRSF17, TNFRSF18, TNFRSF19, and TNFRSF20.
- 7. The fusion polypeptide of claim 6, wherein the polypeptide is capable of inhibiting signaling of a tumor necrosis family receptor super family signaling.
- 8. The fusion polypeptide of claim 7, wherein said first and second polypeptides of said fusion polypeptide are encoded by nucleic acids derived from a human.
- 9. The fusion polypeptide of claim 8, wherein said fusion polypeptide is non-immunogenic.
- 10. The fusion polypeptide of claim 5, wherein the second polypeptide is a soluble portion of a polypeptide selected from the group consisting of TNFSF1, TNFSF2, TNFSF3, TNFSF4, TNFSF5, TNFSF6, TNFSF7, TNFSF8, TNFSF9, TNFSF10, TNFSF11, TNFSF12, TNFSF13, TNFSF14, TNFSF15, TNFSF16, TNFSF17, TNFSF18, TNFSF19, and TNFSF20.
- 11. The fusion polypeptide of claim 10, wherein tumor necrosis family receptor super family signaling is enhanced.
- 12. The fusion polypeptide of claim 11, wherein said first and second polypeptides of said fusion polypeptide are encoded by nucleic acids derived from a human.
- 13. The fusion polypeptide of claim 12, wherein said fusion polypeptide is capable of forming a multimer of a trimer.
- 14. The fusion polypeptide of claim 13, wherein the second heterologous polypeptide comprises the amino acids depicted as amino acids 96 to 244 of SEQ ID NO:6.
- 15. A nucleic acid encoding the polypeptide of any one of claims 1, 2 or 3.
- 16. A host cell comprising a nucleic acid of claim 15, wherein said nucleic acid is operably linked to a heterologous control element.
- 17. A host cell transfected with a nucleic acid according to claim 15.
- 18. A method of producing a polypeptide encoded by the nucleic acid of claim 15, comprising the steps of growing a host cell transfected with said nucleic acid in conditions favorable for expression of the polypeptide, and isolating said polypeptide.
- 19. A recombinant vector comprising the nucleic acid of claim 15.
- 20. A method of constructing a recombinant expression vector comprising the steps of linking a first nucleic acid comprising nucleotides x to y of the nucleic acid depicted in SEQ ID NO:9, wherein x is 331 to 508, and y is 546 to 808, and a second nucleic acid encoding a heterologous polypeptide to the first nucleic acid into a compatible cloning site of an expression vector, followed by amplifying and isolating said recombinant expression vector.
- 21. The method of claim 20, wherein the second nucleic acid encodes a soluble portion of a polypeptide selected from the group consisting of TNFSF1, TNFRSF1A, TNFSF2, TNFRSF1B, TNFSF3, TNFRSF3, TNFSF4, TNFRSF4, TNFSF5, TNFRSF5, TNFSF6, TNFRSF6, TNFRSF6B, TNFSF7, TNFRSF7, TNFSF8, TNFRSF8, TNFSF9, TNFRSF9, TNFSF10, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFSF11, TNFRSF11A, TNFRSF11B, TNFSF12, TNFRSF12, TNFRSF12L, TNFSF13, TNFRSF13, TNFSF13B, TNFSF14, TNFRSF14, TNFSF15, TNFRSF15, TNFSF16, NFRSF16, TNFSF17, TNFRSF17, TNFSF18, TNFRSF18, TNFSF19, TNFRSF19, TNFSF20, and TNFRSF20.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application No. 60/343,315, filed Dec. 21, 2001 which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60343315 |
Dec 2001 |
US |